P78 Subjects who underwent bowel scope screening are significantly more likely to return FOBt/FIT screening kits
Year: 2021
Type: conference-paper
Study design: Observational Study
Abstract: Introduction Bowel Scope screening (BoSS) was launched in 2013 for individuals aged 55 after a landmark study showed that sigmoidoscopy based colorectal cancer (CRC) screening reduced cancer incidence by 23%.1 Longer term follow up in this study showed that the protection given by sigmoidoscopy based screening from colorectal cancer lasted at least 17 years.2 What is not known is how subjects who underwent BoSS at age 55, would interact with the home faecal occult blood/immunochemical test (FOBt/FIT) based screening offered at age 60, compared to non-BoSS screened subjects engaging who engage with FOBt/FIT. Methods 429 Northamptonshire subjects who underwent BoSS in 2014 had their interaction with the FOBt/FIT screening in 2019 recorded and analysed, benchmarked against non-BoSS screened subjects’ data (from Exeter database dashboard; 2017 & 2018). Results 429 subjects’ data analysed, 205 females (47.8%), 412 subjects attended a BoSS examination. 30/412 had ≥ 1 adenoma (7.3%). 304/412 returned a FOBt/FIT kit (73.8%), 5/304 were positive (1.6%), one patient diagnosed with CRC. One FOBt/FIT non-responder diagnosed with CRC. Conclusion The cohort of subjects who underwent BoSS in 2014 were significantly more likely to return FOBt/FIT kits when compared to a non-BoSS screened population (benchmarked with data from 2017 & 2018), Even considering the switch to FIT from FOBT during 2019, the marked improvement in returns suggests that the majority of subjects who underwent BoSS found it a positive experience making them much more likely to engage with FOBt/FIT at the age of 60 and older. Despite the higher uptake, the positivity rate is lower for the BoSS cohort than the non-BoSS screened population. The sample size is too small to reach statistical significance, but if this trend for lower positivity is established when looking a bigger sample (eg; all the regions of England), this may represent the benefits shown in the original studies. 1, 2 References W S Atkin, R Edwards, I Kralj-Hans, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624–1633. W S Atkin, K Wooldrage, D M Parkin, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening Trial. Lancet 2017; 389: 1299–1311.
Source: Gut
Authors: Tania Baldwin, Ajay Verma
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3121676312